| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
Form 4: te Boekhorst Paul Francis Olivier, Director
Received 16,393 shares by exercise or conversion ($100K) |
| 13 Nov 2026 | 8-K: Results of Operations and Financial Condition |
| 12 Nov 2026 | FORM 10-Q |
| 12 Nov 2026 | FORM S-8 |
| 13 Oct 2026 |
8-K: Results of Operations and Financial Condition
ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results |
| 13 Aug 2026 | FORM 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today ann... |
| 09 Jul 2026 |
8-K: Results of Operations and Financial Condition
ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results |
| 22 Jun 2026 |
Form 4: te Boekhorst Paul Francis Olivier, Director
Bought 8,000 shares ($76K) |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders of the Company (the “2026 Annual Meeting”) was held by remote communication in the form of both a dial-in conference call and an audio webcast rather than an in-person event on Thursday, June 11, 2... |
| 10 Jun 2026 |
8-K: Regulation FD Disclosure
In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equip... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
PORTLAND, Maine – May 14, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudi... |
| 14 May 2026 | FORM 10-Q |
| 13 May 2026 | FORM 10-K/A |
| 08 May 2026 |
8-K: Entry into a Material Definitive Agreement
On May 8, 2026, ImmuCell Corporation and Norbrook Laboratories Limited (incorporated and registered in Northern Ireland) entered into a Settlement Deed to resolve and release any and all claims arising out of or relating to an underlying... |
| 24 Apr 2026 |
Proxy statement: annual meeting on June 11, 2026
CEO pay $676K · say-on-pay vote |
| 23 Apr 2026 | Form 3: DiMarco Anthony, Director |
| 23 Apr 2026 | Form 3: Guillemette Gilles, Director |
| 16 Apr 2026 |
Form 4: Turner Kathy V, Director
Granted 17,899 Non Qualified Stock Options (Right to buy) |
| 16 Apr 2026 |
Form 4: Tomsche David Scott, Director
Granted 11,933 Non Qualified Stock Options (Right to buy) |
Loading...